- Home
- VNDA
as 07-26-2024 4:00pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Upcoming Earnings Alert:
Get ready for potential market movements as Vanda Pharmaceuticals Inc. VNDA prepares to release earnings report on 29 Jul 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 362.6M | IPO Year: | 2006 |
| Target Price: | $11.00 | AVG Volume (30 days): | 799.0K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.30 - $6.75 | Next Earning Date: | 07-29-2024 |
| Revenue: | $177,604,000 | Revenue Growth: | -30.81% |
| Revenue Growth (this year): | 2.98% | Revenue Growth (next year): | 19.49% |
Stock Insider Trading Activity of Vanda Pharmaceuticals Inc. (VNDA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Williams Timothy | VNDA | SVP & General Counsel | Mar 4 '24 | Sell | $4.41 | 8,147 | $35,916.86 | 205,766 | SEC Form 4 |
| Williams Timothy | VNDA | SVP & General Counsel | Mar 4 '24 | Sell | $4.18 | 8,941 | $37,395.73 | 196,825 | SEC Form 4 |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 4 '24 | Sell | $4.24 | 30,884 | $131,065.52 | 1,896,018 | SEC Form 4 |
| Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 4 '24 | Sell | $4.13 | 24,288 | $100,273.01 | 1,871,730 | SEC Form 4 |
| Moran Kevin Patrick | VNDA | SVP, CFO & Treasurer | Mar 4 '24 | Sell | $4.48 | 5,798 | $25,982.00 | 239,916 | SEC Form 4 |
| Moran Kevin Patrick | VNDA | SVP, CFO & Treasurer | Mar 4 '24 | Sell | $4.20 | 8,902 | $37,410.66 | 231,014 | SEC Form 4 |
| Birznieks Gunther | VNDA | SVP, Business Development | Mar 4 '24 | Sell | $4.30 | 8,727 | $37,494.68 | 322,253 | SEC Form 4 |
| Birznieks Gunther | VNDA | SVP, Business Development | Mar 4 '24 | Sell | $4.13 | 8,684 | $35,884.02 | 313,569 | SEC Form 4 |
| Wijkstrom Joakim | VNDA | SVP, Chief Marketing Officer | Mar 4 '24 | Sell | $4.41 | 7,498 | $33,090.92 | 139,018 | SEC Form 4 |
| Wijkstrom Joakim | VNDA | SVP, Chief Marketing Officer | Mar 4 '24 | Sell | $4.21 | 9,229 | $38,830.09 | 129,789 | SEC Form 4 |
Latest Vanda Pharmaceuticals Inc. News
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
PR Newswire
11 hours ago
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
MT Newswires
25 days ago
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz
PR Newswire
a month ago
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
BioPharma Dive
a month ago
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
PR Newswire
a month ago
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
MT Newswires
a month ago
Sector Update: Health Care Stocks Ease Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Thursday Afternoon
MT Newswires
a month ago
Sector Update: Health Care
Compare VNDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.